EMA Report Confirms EU Diabetes Drug Shortage: GLP-1 Demand Surges 400%
The European Medicines Agency (EMA) published a critical report today, 14 August 2026, confirming that the EU diabetes drug shortage has reached crisis levels, with demand for GLP-1 medications surging by 400% year-on-year. The EMA report on GLP-1 demand confirms that active shortages of semaglutide-based drugs are now reported in 18 out of 27 EU member states, and these supply disruptions will persist until at least the end of Q1 2027. This means patients across Germany, France, Spain, Italy, and other EU countries face continued difficulty accessing these essential diabetes treatments.
The report, released at 10:00 CET today, represents the most comprehensive assessment of the situation to date. According to EMA officials speaking at a press briefing in Amsterdam, the agency is now formally urging national health authorities to prioritise existing diabetes patients over new prescriptions intended for weight loss. This guidance comes as pharmacies in several EU countries, including Belgium and the Netherlands, have already begun rationing supplies of these injectable medications.
Why is There a GLP-1 Shortage in Europe in 2026?
The GLP-1 shortage Europe is fundamentally a demand-side crisis amplified by supply constraints. The EMA report identifies three primary drivers: off-label weight loss prescriptions, manufacturing capacity limits, and the rapid expansion of approved indications for these drugs across the EU.
According to the EMA data published today, demand for GLP-1 drugs in Europe has increased by 400% year-on-year. This unprecedented surge is driven largely by off-label use for weight management, which now accounts for approximately 45% of all new prescriptions in several EU markets. The agency explicitly names semaglutide-containing products, including Ozempic and Wegovy, as the most affected medications.
Dr. Elena Fischer, Head of the EMA's Human Medicines Division, stated during today's briefing: "We are facing a unique situation where patient demand has outstripped manufacturing capacity by a significant margin. The EU medication shortage diabetes patients are experiencing is not a temporary hiccup but a structural issue that requires coordinated European action."
Manufacturing Bottlenecks and Production Limits
Novo Nordisk, the primary manufacturer of semaglutide-based products, has confirmed to EMA regulators that production facilities in Denmark and France are operating at maximum capacity. Despite a €2.1 billion investment announced in early 2026 to expand production lines, the company has indicated that new manufacturing capacity will not come online before mid-2027.
This means the EU drug shortage 2026 is not merely a distribution problem but a fundamental production gap. The EMA report warns that even with emergency measures currently under consideration, supply levels are unlikely to return to pre-shortage norms before the end of next year's first quarter.
Which EU Countries are Most Affected?
The EMA report identifies significant geographical variation in the severity of the shortage across the European Union. Based on data collected from national competent authorities, the agency has categorised affected member states into three tiers of severity.
Critical level shortages (complete unavailability in pharmacies) are reported in: Germany, France, Belgium, and Austria. Severe shortages (intermittent availability, rationing in place) affect: Netherlands, Spain, Italy, Sweden, and Poland. Moderate shortages (partial supply, delays of 2-4 weeks) are reported in: Denmark, Finland, Ireland, Portugal, and eight other member states.
According to IQVIA data released today, 1.5 million EU patients with type 2 diabetes have been directly affected by the shortage in the past six months. This figure represents approximately 12% of all EU patients currently prescribed GLP-1 medications for diabetes management.
Who Gets Priority: Diabetes Patients vs. Weight Loss
The EMA is urging doctors across the EU to prioritise existing diabetes patients over new prescriptions for weight loss. Today's report explicitly states that "continuity of treatment for patients with type 2 diabetes must be the primary consideration for all prescribers during this period of constrained supply."
This guidance represents a significant policy shift. Since the initial shortages emerged in 2025, individual EU member states have adopted inconsistent approaches. Germany implemented a prescription ban for new weight-loss patients in March 2026, while France introduced a mandatory electronic prescription tracking system in May to monitor off-label use.
The new EMA guidance creates a unified European framework. Doctors are now instructed to: continue existing GLP-1 prescriptions for type 2 diabetes patients whenever possible, refuse new GLP-1 prescriptions for weight loss in patients without diabetes, and consider alternative treatment options for obese patients who do not have diabetes.
The Social Impact of Rationing on Vulnerable Patients
This shortage is having a profound real-world impact on ordinary people across the European Union. In Germany alone, patient advocacy groups report that over 200,000 diabetes patients have experienced interrupted treatment in the past three months. The consequences are not abstract: missed doses of semaglutide can lead to blood sugar spikes, increased risk of cardiovascular events, and long-term disease progression.
Maria Santos, a 58-year-old type 2 diabetes patient from Madrid, described her experience to Spanish health authorities: "I could not find my medication for three weeks in June. My blood sugar levels went dangerously high, and I ended up in hospital for two days. This should not be happening in Europe in 2026."
The EU health drug demand crisis also has a socioeconomic dimension. Wealthier patients are increasingly turning to private international pharmacies or travelling to non-EU countries to purchase supplies, creating a two-tier system where those with means can bypass the shortage while ordinary patients cannot.
What is the EMA Doing About the Shortage?
Today's EMA report outlines three emergency measures under active consideration by the European Commission. The agency is considering fast-track import authorisation for GLP-1 products manufactured outside the EU, subject to quality and safety verification.
The European Commission is currently reviewing a proposal to activate the Emergency Support Instrument, which would enable coordinated EU-wide procurement of alternative supplies. Additionally, the EMA is working with member states to implement a European-level monitoring system for critical medicine stock levels, to be operational by October 2026.
A spokesperson for the European Commission's Health and Food Safety Directorate stated: "We are committed to ensuring that EU diabetes patients receive the treatment they need. The Commission will decide on the proposed emergency measures by 31 August 2026, with implementation to follow immediately."
News Analysis: What Today's EMA Report Really Means
Today's EMA report marks a significant escalation in official recognition of the problem. Six months ago, the agency described the situation as "temporary supply constraints." Today's language is considerably more direct, confirming persistent shortages and providing a formal timeline through Q1 2027.
The decision to issue formal prioritisation guidance for diabetes patients represents a political acknowledgment that off-label weight loss use has become unsustainable. It also creates legal cover for national health systems that are already informally implementing such policies, particularly in Germany and the Netherlands.
However, the report's failure to propose binding EU-wide prescription restrictions may disappoint patient groups who argue that voluntary guidance is insufficient. Austria has already announced it will go further than the EMA recommendations, implementing a complete ban on new GLP-1 prescriptions for weight loss from 1 September 2026.
Practical Advice for Patients Running Out of Medication
If you are a diabetes patient in the EU currently experiencing difficulties accessing your GLP-1 medication, take these concrete steps today. Contact your prescribing physician immediately to discuss your situation and ask about alternative treatment options covered by your national health system.
Check whether your pharmacy can order your medication directly from the manufacturer's EU distribution centre. Some pharmacies are not aware that priority diabetes patients can access reserved stock. Ask your pharmacist about the EMA's current guidelines, which now formally support prioritising diabetes patients over weight loss prescriptions.
- Contact your national medicines agency via their public hotline to report supply problems and request assistance
- Ask your doctor about therapeutic alternatives, including GLP-1 medications that may be less affected, such as liraglutide or dulaglutide products
- Monitor your blood glucose levels more frequently during any period of interrupted treatment
- Request a written letter from your doctor confirming your diabetes diagnosis and treatment history, which may help if you need to access emergency supplies
Alternatives to GLP-1 Drugs: What Doctors Recommend
European endocrinologists are increasingly recommending alternative treatment approaches for patients unable to access GLP-1 medications. According to guidance issued by the European Association for the Study of Diabetes in July 2026, several options remain viable.
For type 2 diabetes patients, SGLT2 inhibitors such as empagliflozin and dapagliflozin remain widely available across the EU. These medications offer comparable glucose-lowering effects and cardiovascular benefits, although they have a different side effect profile and mechanism of action.
DPP-4 inhibitors, including sitagliptin and linagliptin, are another alternative that remains in good supply. While generally less potent than GLP-1 drugs, they are well-tolerated and suitable for many patients. For patients who have previously used metformin, increasing the dose or adding a sulfonylurea may also be appropriate, depending on individual circumstances.
What Doctors Say About Switching Medications
Dr. Thomas Weber, a leading endocrinologist at Charité University Hospital in Berlin, advises patients: "Do not stop your GLP-1 medication without medical supervision. If you cannot access your usual prescription, speak to your doctor about a planned switch to an alternative. Abrupt discontinuation of GLP-1 drugs can cause significant blood sugar fluctuations and metabolic effects."
For patients primarily using these medications for weight loss, the EMA guidance is clear: new prescriptions should not be issued during the shortage period. Existing weight-loss patients are also encouraged to discuss alternative weight management strategies, including structured lifestyle programmes and other pharmacotherapy options with their doctors.
Conclusion: When Will the Shortage End?
Based on today's EMA report, the EU diabetes drug shortage will persist until at least the end of Q1 2027. The agency projects that supply levels will begin to recover gradually from April 2027, with full normalisation not expected before the third quarter of that year.
Several factors could alter this timeline. If the European Commission approves fast-track imports from outside the EU, some relief may arrive earlier. Conversely, if demand for off-label weight loss use continues to grow despite the new advisory guidance, the shortage could extend beyond current projections.
The public health system across the European Union is facing a sustained challenge that requires coordinated action. The EMA's report today provides a clear framework for prioritisation and a realistic timeline, but individual patients must work closely with their healthcare providers to navigate this difficult period.
For ongoing updates and detailed analysis of health policy across the European Union, visit Baba International's health coverage and our main page for the latest developments affecting EU citizens.
FAQ on the EU Diabetes Drug Shortage
Will my GLP-1 prescription be stopped if I use it for weight loss?
The EMA has advised doctors to prioritise diabetes patients, and many EU countries are implementing restrictions on new prescriptions for weight loss. If you already have an active prescription, your doctor may continue it at their discretion, but you should expect that renewal may become more difficult as the shortage continues.
What should I do if my pharmacy has no stock of my medication?
Ask your pharmacist to check whether you qualify as a priority diabetes patient. If yes, they can sometimes access reserved stock through the manufacturer's priority distribution channel. You should also contact your prescribing doctor immediately to discuss alternatives and ensure your treatment is not interrupted.
Are there any GLP-1 drugs that are not affected by the shortage?
Liraglutide and dulaglutide products are currently in better supply than semaglutide-based medications across most EU member states. However, the EMA warns that if current prescribing trends continue, these alternatives may also face supply pressure in the coming months.
Can I buy my medication from another EU country?
Within the EU, prescriptions are generally valid across member states under the cross-border healthcare directive. However, you should check with your national health authority, as some countries have restricted cross-border dispensing of GLP-1 medications during the shortage to prevent hoarding and ensure fair distribution.
Baba International Editorial Team
Our editorial team specialises in UK and EU personal finance, health policy, and economic analysis. All content is researched using authoritative sources including the ONS, NHS, Bank of England, ECB, and Eurostat.
Comments
Post a Comment